NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

Search

Zealand Pharma A-S

Închisă

312.39 -6.61

Rezumat

Modificarea prețului

24h

Curent

Minim

310.39

Maxim

324.2

Indicatori cheie

By Trading Economics

Venit

-15M

-394M

Vânzări

-35M

34M

P/E

Medie Sector

3.877

51.415

EPS

-5.58

Marjă de profit

-1,158.824

Angajați

544

EBITDA

-26M

-529M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+25.15% upside

Dividende

By Dow Jones

Următoarele câștiguri

13 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

3.4B

24B

Deschiderea anterioară

319

Închiderea anterioară

312.39

Zealand Pharma A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mar. 2026, 09:24 UTC

Principalele dinamici ale pieței

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

6 mar. 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

Comparație

Modificare preț

Zealand Pharma A-S Așteptări

Obiectiv de preț

By TipRanks

25.15% sus

Prognoză pe 12 luni

Medie 270.582 DKK  25.15%

Maxim 270.568 DKK

Minim 270.568 DKK

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruZealand Pharma A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

0

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
help-icon Live chat